Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 15, 2022 08:00 ET | Source: InspireMD Inc.

InspireMD Announces Adnan Siddiqui, MD, PhD as a Member of its Scientific Advisory Board and Strategic Advisor

TEL AVIV, Israel, Feb. 15, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), a global developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery...
January 27, 2022 08:00 ET | Source: InspireMD Inc.

InspireMD to Present at the 16th Biennial Scientific Meeting of the International Andreas Gruentzig Society (IAGS)

TEL AVIV, Israel, Jan. 27, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for prevention of stroke caused by Carotid Artery...
January 18, 2022 08:11 ET | Source: InspireMD Inc.

InspireMD Announces Live Case Broadcast at ISET 2022 Conference Following the Supplement Approval by the FDA Regarding its Pivotal C-Guardians Trial

TEL AVIV, Israel, Jan. 18, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for prevention of stroke caused by Carotid Artery...
November 09, 2021 07:30 ET | Source: InspireMD Inc.

InspireMD Reports Third Quarter 2021 Financial Results and Provides Corporate Update

-CGuard™ sales generated 24% YoY revenue growth- -CGuard™ EPS received a positive opinion from the French National Authority for Health (HAS) regarding reimbursement in France- - $37.1 million in...
November 03, 2021 16:05 ET | Source: InspireMD Inc.

InspireMD Announces Publication of 12-Month Results of CGuard™ EPS SIBERIA Trial in Journals of the American College of Cardiology: Cardiovascular Interventions

TEL AVIV, Israel, Nov. 03, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of...
October 26, 2021 08:30 ET | Source: InspireMD Inc.

InspireMD to Report Third Quarter 2021 Financial Results on November 9, 2021 and Provide Corporate Business Update

TEL AVIV, Israel, Oct. 26, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease...
October 13, 2021 08:30 ET | Source: InspireMD Inc.

InspireMD Receives Reimbursement Approval for CGuard™ Embolic Prevention System from the French National Authority for Health

TEL AVIV, Israel, Oct. 13, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), a global developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery...
August 10, 2021 07:00 ET | Source: InspireMD Inc.

InspireMD Announces Strong Second Quarter 2021 Financial Results

Revenue rebound, strong procedural recovery Management to host investor conference call today, August 10, 2021, at 8:30am ET TEL AVIV, Israel, Aug. 10, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc....
August 04, 2021 08:30 ET | Source: InspireMD Inc.

InspireMD to Report Second Quarter 2021 Financial Results on Tuesday, August 10, 2021, and Provide Corporate Update

TEL AVIV, Israel, Aug. 04, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease...
July 23, 2021 08:30 ET | Source: InspireMD Inc.

InspireMD Enrolls and Treats First Patients at Ballad Health System in U.S. Registration C-Guardian Clinical Trial of CGuard EPS

TEL AVIV, Israel, July 23, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right